27764829|t|Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes
27764829|a|Determination of the mutant prevention concentration (MPC) and the mutant selection window (MSW) of antimicrobial agents used to treat pathogenic bacteria is important in order to apply effective antimicrobial therapies. Here, we determined the MPCs of the major topical antimicrobial agents against Propionibacterium acnes and Staphylococcus aureus which cause skin infections and compared their MSWs. Among the MPCs of nadifloxacin and clindamycin, the clindamycin MPC was determined to be the lowest against P. acnes. In contrast, the nadifloxacin MPC was the lowest against S. aureus. Calculations based on the minimum inhibitory concentrations and MPCs showed that clindamycin has the lowest MSW against both P. acnes and S. aureus. Nadifloxacin MSWs were 4-fold higher against P. acnes than against S. aureus. It is more likely for P. acnes to acquire resistance to fluoroquinolones than S. aureus. Therefore, topical application of clindamycin contributes very little to the emergence of resistant P. acnes and S. aureus strains.
27764829	21	52	Mutant Prevention Concentration	T061	C1273380
27764829	61	84	Mutant Selection Window	T081	C0001555
27764829	88	116	Topical Antimicrobial Agents	T121	C1136255
27764829	125	148	Propionibacterium acnes	T007	C0033477
27764829	170	201	mutant prevention concentration	T061	C1273380
27764829	203	206	MPC	T061	C1273380
27764829	216	239	mutant selection window	T081	C0001555
27764829	241	244	MSW	T081	C0001555
27764829	249	269	antimicrobial agents	T121	C1136254
27764829	284	294	pathogenic	T001	C0450254
27764829	295	303	bacteria	T007	C0004611
27764829	345	358	antimicrobial	T121	C1136254
27764829	359	368	therapies	T061	C0087111
27764829	394	398	MPCs	T061	C1273380
27764829	412	440	topical antimicrobial agents	T121	C1136255
27764829	449	472	Propionibacterium acnes	T007	C0033477
27764829	477	498	Staphylococcus aureus	T007	C0038172
27764829	511	526	skin infections	T047	C0162627
27764829	546	550	MSWs	T081	C0001555
27764829	562	566	MPCs	T061	C1273380
27764829	570	582	nadifloxacin	T109,T195	C0286402
27764829	587	598	clindamycin	T109,T195	C0008947
27764829	604	615	clindamycin	T109,T195	C0008947
27764829	616	619	MPC	T061	C1273380
27764829	645	651	lowest	T080	C1708760
27764829	660	668	P. acnes	T007	C0033477
27764829	687	699	nadifloxacin	T109,T195	C0286402
27764829	700	703	MPC	T061	C1273380
27764829	712	718	lowest	T080	C1708760
27764829	727	736	S. aureus	T007	C0038172
27764829	738	750	Calculations	T057	C1956058
27764829	764	797	minimum inhibitory concentrations	T034	C1304747
27764829	802	806	MPCs	T061	C1273380
27764829	819	830	clindamycin	T109,T195	C0008947
27764829	839	845	lowest	T080	C1708760
27764829	846	849	MSW	T081	C0001555
27764829	863	871	P. acnes	T007	C0033477
27764829	876	885	S. aureus	T007	C0038172
27764829	887	899	Nadifloxacin	T109,T195	C0286402
27764829	900	904	MSWs	T081	C0001555
27764829	917	923	higher	T080	C0205250
27764829	932	940	P. acnes	T007	C0033477
27764829	954	963	S. aureus	T007	C0038172
27764829	987	995	P. acnes	T007	C0033477
27764829	1007	1017	resistance	T038	C0013203
27764829	1021	1037	fluoroquinolones	T109,T121	C0949665
27764829	1043	1052	S. aureus	T007	C0038172
27764829	1065	1084	topical application	T061	C0683174
27764829	1088	1099	clindamycin	T109,T195	C0008947
27764829	1144	1153	resistant	T038	C0013203
27764829	1154	1162	P. acnes	T007	C0033477
27764829	1167	1176	S. aureus	T007	C0038172